Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders

5 May 2015

Abstract excerpt

The differentiation between multiple system atrophy (MSA) and Parkinson's disease (PD) is difficult, particularly in early disease stages. Therefore, we aimed to evaluate the diagnostic value of neurofilament light chain (NFL), fms-like tyrosine kinase ligand (FLT3L), and total tau protein (t-tau) in cerebrospinal fluid (CSF) as biomarkers to discriminate MSA from PD. Using commercially available enzyme-linked...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurological diseases and metabolism
Share to Neurological disorders and treatments
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25999911
DOI: 10.3389/fneur.2015.00091

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian DisordersPMID 25999911Read ↗

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease ProgressionSemantic proximity Read ↗

Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapiesSemantic proximity Read ↗

Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study.Semantic proximity Read ↗

The Many Faces of Parkinsonism: Dissecting Clinical and Molecular Overlap in Multiple System Atrophy and Parkinson's DiseaseSemantic proximity Read ↗

Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models.Semantic proximity Read ↗

Neurofilament light chain: a biomarker for genetic frontotemporal dementiaSemantic proximity Read ↗

Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics.Semantic proximity Read ↗

Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob diseaseSemantic proximity Read ↗

Plasma Neurofilament Light Chain and Clinical Diagnosis in Frontotemporal Dementia SyndromesSemantic proximity Read ↗

Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementiaSemantic proximity Read ↗

Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.Semantic proximity Read ↗

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.